Concise Total Synthesis of (-)-Quinocarcin Enabled by Catalytic Enantioselective Reductive 1,3-Dipolar Cycloaddition of Secondary Amides.

Angew Chem Int Ed Engl

Fujian Provincial Key Laboratory of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian, 361005, P. R. China.

Published: June 2023

A concise asymmetric total synthesis of (-)-quinocarcin has been accomplished with high step economy from commercially available starting materials. A catalytic enantioselective reductive 1,3-dipolar cycloaddition reaction of N-heteroaryl secondary amides with reactive dipolarophiles using iridium/copper relay catalysis was developed to prepare the key chiral pyrrolidine intermediate with three stereocenters. This protocol features excellent regio-, exo- and enantioselectivities, broad substrate scope, and good functional group tolerance. The high efficiency was also ensured by a Rh -catalyzed C-H activation/cyclization and a tandem diastereoselective hydrogenation/cyclization to construct the tetrahydroisoquinoline-pyrrolidine tetracyclic core unit of quinocarcin.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.202302832DOI Listing

Publication Analysis

Top Keywords

total synthesis
8
synthesis --quinocarcin
8
catalytic enantioselective
8
enantioselective reductive
8
reductive 13-dipolar
8
13-dipolar cycloaddition
8
secondary amides
8
concise total
4
--quinocarcin enabled
4
enabled catalytic
4

Similar Publications

Background/objectives: A "people-centered" approach is one of the core principles of the Immunization Agenda (IA) 2030 and emphasizes the need for services to be organized around the needs and expectations of individuals and the community. A better understanding of the immunization experience from the client's perspective is key to guiding the design of policies and interventions aimed at improving immunization delivery and coverage. This study provides a synthesis of the immunization experiences of children's caregivers in Cameroon, highlighting potential barriers for timely and complete immunization.

View Article and Find Full Text PDF

Background: The emergence of new COVID-19 variants continues to affect healthcare workers (HCWs) and vulnerable populations in the post-pandemic era. This study aims to assess the willingness, perceptions, and factors associated with booster COVID-19 vaccine uptake in this context.

Methods: A cross-sectional study was conducted between October 2023 and May 2024 among Thai adults (>20 years old) in Chiang Mai, Northern Thailand.

View Article and Find Full Text PDF

SPT-07A, a D-borneol, is currently being developed in China for the treatment of ischemic stroke. We aimed to create a whole-body physiologically-based pharmacokinetic (PBPK) model to predict the pharmacokinetics of SPT-07A in rats, dogs, and humans. The in vitro metabolism of SPT-07A was studied using hepatic, renal, and intestinal microsomes.

View Article and Find Full Text PDF

, an active component of Arnebia euchroma (Royle) Johnst., has remarkable pharmacological effects, particularly in its anti-tumour activity. Nonetheless, the specific targets and mechanisms of action remain to be further explored.

View Article and Find Full Text PDF

Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of synthesis methods to minimize the formation of possible radiochemical impurities, is integral to the implementation of high-tech nuclear medicine procedures. PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [Lu]Lu-PSMA-617 and [Lu]Lu-PSMA have achieved global recognition as viable radiopharmaceuticals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!